Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 06:05PM GMT
Release Date Price: €30.97
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. I think we'll get started with the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have Denali with us for the next session.

Briefly before we get started, I need to read a disclosure statement. So please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosure.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So with that, really pleased to have Ryan Watts, the CEO of Denali with us. Ryan, maybe just like an overarching question to start out, which is, I think, since Denali came public, we've seen a lot more companies come into the neurodegeneration space. I think everybody is not necessarily focused on the same targets or even focused on the same disease areas, but just broadly, as you think about the scope of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot